Adage Capital Partners
FOLD

Adage Capital Partners’s Amicus Therapeutics FOLD Stock Holding History

Adage Capital Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.9M Hold
1,650,000
– – 0.04% 425
2025
Q4 		$23.5M Buy
+1,650,000
New +$16.2M 0.04% 430
2022
Q3 		– Sell
-848,157
Closed -$9.11M – 1069
2022
Q2 		$9.11M Buy
848,157
+298,157
+54% +$2.46M 0.02% 692
2022
Q1 		$5.21M Buy
+550,000
New +$5.16M 0.01% 827
2018
Q2 		– Sell
-1,450,000
Closed -$21.8M – 755
2018
Q1 		$21.8M Buy
+1,450,000
New +$22.1M 0.05% 378

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Adage Capital Partners's FOLD Position: Q1 2026 in Review

Adage Capital Partners held its Amicus Therapeutics (FOLD) position steady in Q1 2026 at 1,650,000 shares worth $23.9M. The position accounts for 0.04% of the portfolio, ranked #425.

Adage Capital Partners first reported a position in FOLD in Q1 2018 and has held it in 5 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Adage Capital Partners held 1,650,000 shares of Amicus Therapeutics worth $23.9M as of Q1 2026.
  • Adage Capital Partners left its Amicus Therapeutics share count unchanged in Q1 2026.
  • Amicus Therapeutics made up 0.04% of Adage Capital Partners's portfolio in Q1 2026, its #425 holding.
  • Adage Capital Partners first reported a position in Amicus Therapeutics in Q1 2018 and has held it in 5 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.